Company profile
Zai Lab Ltd
NASDAQ:ZLABBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Niraparib | phase3 | — | 6 | completed, terminated, unknown |
| Zocilurtatug Pelitecan | phase3 | — | 4 | active |
| RIPRETINIB | phase2 | — | 1 | no active trials |
| ADAGRASIB | phase1 | — | 18 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05859464 | phase1 | terminated | 2023-07-24 | 2025-08-28 | Zai Lab (Hong Kong), Ltd. | A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors |
| NCT07658482 | phase1 | not_yet_recruiting | 2026-09-03 | 2027-02-06 | Zai Lab (Shanghai) Co., Ltd. | A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers |
| NCT07235384 | phase1 | recruiting | 2025-12-01 | 2027-12-28 | Zai Lab (Shanghai) Co., Ltd. | A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis |
| NCT03516071 | phase2 | completed | 2017-05-17 | 2018-11-09 | Zai Lab (Shanghai) Co., Ltd. | A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC |
| NCT06380907 | phase2 | terminated | 2024-05-22 | 2025-12-16 | Zai Lab (Hong Kong), Ltd. | A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis |
FDA applications (0)
No records yet.